|
1
|
Sorosky JI: Endometrial cancer. Obstet
Gynecol. 120:383–397. 2012. View Article : Google Scholar
|
|
2
|
Matsuda T, Marugame T, Kamo K, et al:
Cancer incidence and incidence rates in Japan in 2006: based on
data from 15 population-based cancer registries in the monitoring
of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol.
42:139–147. 2012. View Article : Google Scholar
|
|
3
|
Aggarwal P and Kehoe S: Serum tumour
markers in gynaecological cancers. Maturitas. 67:46–53. 2010.
View Article : Google Scholar
|
|
4
|
Larson DM, Connor GP, Broste SK, Krawisz
BR and Johnson KK: Prognostic significance of gross myometrial
invasion with endometrial cancer. Obstet Gynecol. 88:394–398. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nakao Y, Yokoyama M, Hara K, et al: MR
imaging in endometrial carcinoma as a diagnostic tool for the
absence of myometrial invasion. Gynecol Oncol. 102:343–347. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Randall ME, Filiaci VL, Muss H, et al:
Randomized phase III trial of whole-abdominal irradiation versus
doxorubicin and cisplatin chemotherapy in advanced endometrial
carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol.
24:36–44. 2006. View Article : Google Scholar
|
|
7
|
Aapro MS, van Wijk FH, Bolis G, et al:
Doxorubicin versus doxorubicin and cisplatin in endometrial
carcinoma: definitive results of a randomised study (55872) by the
EORTC Gynaecological Cancer Group. Ann Oncol. 14:441–448. 2003.
View Article : Google Scholar
|
|
8
|
Akram T, Maseelall P and Fanning J:
Carboplatin and paclitaxel for the treatment of advanced or
recurrent endometrial cancer. Am J Obstet Gynecol. 192:1365–1367.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Michener CM, Peterson G, Kulp B, Webster
KD and Markman M: Carboplatin plus paclitaxel in the treatment of
advanced or recurrent endometrial carcinoma. J Cancer Res Clin
Oncol. 131:581–584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamada K, Tanabe H, Imai M, et al:
Feasibility study of paclitaxel plus carboplatin in patients with
endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial). J
Obstet Gynaecol Res. 39:311–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lax SF, Kendall B, Tashiro H, Slebos RJ
and Hedrick L: The frequency of p53, K-ras mutations, and
microsatellite instability differs in uterine endometrioid and
serous carcinoma: evidence of distinct molecular genetic pathways.
Cancer. 88:814–824. 2000. View Article : Google Scholar
|
|
12
|
Lax SF, Pizer ES, Ronnett BM and Kurman
RJ: Clear cell carcinoma of the endometrium is characterized by a
distinctive profile of p53, Ki-67, estrogen, and progesterone
receptor expression. Hum Pathol. 29:551–558. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Catasus L, Machin P, Matias-Guiu X and
Prat J: Microsatellite instability in endometrial carcinomas:
clinicopathologic correlations in a series of 42 cases. Hum Pathol.
29:1160–1164. 1998. View Article : Google Scholar
|
|
14
|
Kobayashi K, Matsushima M, Koi S, et al:
Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in
sporadic endometrial carcinomas with microsatellite instability.
Jpn J Cancer Res. 87:141–145. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Simpkins SB, Bocker T, Swisher EM, et al:
MLH1 promoter methylation and gene silencing is the primary cause
of microsatellite instability in sporadic endometrial cancers. Hum
Mol Genet. 8:661–666. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanaya T, Kyo S, Maida Y, et al: Frequent
hypermethylation of MLH1 promoter in normal endometrium of patients
with endometrial cancers. Oncogene. 22:2352–2360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
King SA, Adas AA, LiVolsi VA, et al:
Expression and mutation analysis of the p53 gene in uterine
papillary serous carcinoma. Cancer. 75:2700–2705. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peyssonnaux C and Eychene A: The
Raf/MEK/ERK pathway: new concepts of activation. Biol Cell.
93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saegusa M, Hashimura M, Yoshida T and
Okayasu I: Beta-catenin mutations and aberrant nuclear expression
during endometrial tumorigenesis. Br J Cancer. 84:209–217. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zysman M, Saka A, Millar A, Knight J,
Chapman W and Bapat B: Methylation of adenomatous polyposis coli in
endometrial cancer occurs more frequently in tumors with
microsatellite instability phenotype. Cancer Res. 62:3663–3666.
2002.PubMed/NCBI
|
|
21
|
Kamat AA, Merritt WM, Coffey D, et al:
Clinical and biological significance of vascular endothelial growth
factor in endometrial cancer. Clin Cancer Res. 13:7487–7495. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aghajanian C, Sill MW, Darcy KM, et al:
Phase II trial of bevacizumab in recurrent or persistent
endometrial cancer: a Gynecologic Oncology Group study. J Clin
Oncol. 29:2259–2265. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zagouri F, Bozas G, Kafantari E, et al:
Endometrial cancer: what is new in adjuvant and molecularly
targeted therapy? Obstet Gynecol Int. 2010:7495792010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coleman RL, Sill MW, Lankes HA, et al: A
phase II evaluation of aflibercept in the treatment of recurrent or
persistent endometrial cancer: a Gynecologic Oncology Group study.
Gynecol Oncol. 127:538–543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McMeekin DS, Sill MW, Benbrook D, et al: A
phase II trial of thalidomide in patients with refractory
endometrial cancer and correlation with angiogenesis biomarkers: a
Gynecologic Oncology Group study. Gynecol Oncol. 105:508–516. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leslie KK, Sill MW, Darcy KM, et al:
Efficacy and safety of gefitinib and potential prognostic value of
soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic
Oncology Group phase II trial of persistent or recurrent
endometrial cancer. J Clin Oncol. 27:e165422009.
|
|
27
|
Jasas KV, Fyles A, Elit L, et al: Phase II
study of erlotinib (OSI 774) in women with recurrent or metastatic
endometrial cancer: NCIC CTG IND-1. J Clin Oncol. 22:e50192004.
|
|
28
|
Takahashi K, Saga Y, Mizukami H, et al:
Cetuximab inhibits growth, peritoneal dissemination, and lymph node
and lung metastasis of endometrial cancer, and prolongs host
survival. Int J Oncol. 35:725–729. 2009.PubMed/NCBI
|
|
29
|
Fleming GF, Sill MW, Darcy KM, et al:
Phase II trial of trastuzumab in women with advanced or recurrent,
HER2-positive endometrial carcinoma: a Gynecologic Oncology Group
study. Gynecol Oncol. 116:15–20. 2010. View Article : Google Scholar
|
|
30
|
Santin AD: Letter to the Editor referring
to the manuscript entitled: ‘Phase II trial of trastuzumab in women
with advanced or recurrent HER2-positive endometrial carcinoma: a
Gynecologic Oncology Group Study’ recently reported by Fleming et
al, (Gynecol Oncol., 116; 15–20;2010). Gynecol Oncol. 118:95–96;
author reply 96–97. 2010.
|
|
31
|
Elsahwi KS and Santin AD: erbB2
overexpression in uterine serous cancer: a molecular target for
trastuzumab therapy. Obstet Gynecol Int. 2011:1282952011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Oza AM, Elit L, Biagi J, et al: Molecular
correlates associated with a phase II study of temsirolimus
(CCI-779) in patients with metastatic or recurrent endometrial
cancer - NCIC IND 160. J Clin Oncol. 24:e30032006.
|
|
33
|
Oza AM, Elit L, Provencher D, et al: A
phase II study of temsirolimus (CCI-779) in patients with
metastatic and/or locally advanced recurrent endometrial cancer
previously treated with chemotherapy: NCIC CTG IND 160 b. J Clin
Oncol. 26:e55162008.
|
|
34
|
Colombo N, McMeekin S, Schwartz P, et al:
A phase II trial of the mTOR inhibitor AP23573 as a single agent in
advanced endometrial cancer. J Clin Oncol. 25:e55162007.
|
|
35
|
Trope C, Johnsson JE, Simonsen E,
Christiansen H, Cavallin-Stahl E and Horvath G: Treatment of
recurrent endometrial adenocarcinoma with a combination of
doxorubicin and cisplatin. Am J Obstet Gynecol. 149:379–381. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nimeiri HS, Oza AM, Morgan RJ, et al: A
phase II study of sorafenib in advanced uterine
carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and
California Phase II Consortia. Gynecol Oncol. 117:37–40. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Takai N, Desmond JC, Kumagai T, et al:
Histone deacetylase inhibitors have a profound antigrowth activity
in endometrial cancer cells. Clin Cancer Res. 10:1141–1149. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tsuruta T, Kozaki K, Uesugi A, et al:
miR-152 is a tumor suppressor microRNA that is silenced by DNA
hypermethylation in endometrial cancer. Cancer Res. 71:6450–6462.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Karaayvaz M, Zhang C, Liang S, Shroyer KR
and Ju J: Prognostic significance of miR-205 in endometrial cancer.
PLoS One. 7:e351582012. View Article : Google Scholar : PubMed/NCBI
|
